APA (7th ed.) Citation

Ye, L., Zheng, N., Liu, F., Fu, H., Liu, Y., Yang, Y., . . . Song, D. (2026). GPR183‐mediated activation of PI3K is a potential biomarker for immunotherapy in lung cancer. Clinical & Translational Discovery, 6(1), 1. https://doi.org/10.1002/ctd2.70119

Chicago Style (17th ed.) Citation

Ye, Ling, et al. "GPR183‐mediated Activation of PI3K Is a Potential Biomarker for Immunotherapy in Lung Cancer." Clinical & Translational Discovery 6, no. 1 (2026): 1. https://doi.org/10.1002/ctd2.70119.

MLA (9th ed.) Citation

Ye, Ling, et al. "GPR183‐mediated Activation of PI3K Is a Potential Biomarker for Immunotherapy in Lung Cancer." Clinical & Translational Discovery, vol. 6, no. 1, 2026, p. 1, https://doi.org/10.1002/ctd2.70119.